drugset / Trial / NCT00354731
Efficacy of Pentoxifylline on Primary Nephrotic Syndrome
Phase 3
Completed
62 enrolled
National Taiwan University Hospital
National Science and Technology Council, Taiwan · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
We aim to investigate (1) the effects of combined pentoxifylline and corticosteroids, compared to that of corticosteroids, on patients with primary nephrotic syndrome; and if possible (2) the effects of pentoxifylline monotherapy on patients with primary nephrotic syndrome not suitable for or intolerant of standard corticosteroid therapy.
Timeline
- Start
- 2006-08
- Primary completion
- 2011-01
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pentoxifylline | Small molecule | 800 mg | Oral |
| Subject | Pentoxifylline | Small molecule | 1200 mg | Oral |
| Background | Prednisolone | Other / unclassified | 0.25 mg | Oral |
| Background | Prednisolone | Other / unclassified | 0.5 mg/kg | Oral |
| Background | Prednisolone | Other / unclassified | 1 mg/kg | Oral |
| Background | Prednisolone | Other / unclassified | 5 mg | Oral |
| Background | Prednisolone | Other / unclassified | 10 mg | Oral |